NASDAQ:CBPOChina Biologic Products Stock Price, Forecast & News Adding Choose a watchlist: Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding China Biologic Products Holdings Inc Please log in to your account or sign up in order to add this asset to your watchlist. Log In and Add $110.69 +0.75 (+0.68 %) (As of 06/4/2020 09:51 AM ET) Add Compare Share Today's Range$109.91Now: $110.69▼$110.6950-Day Range$104.24MA: $107.75▼$110.7752-Week Range$88.00Now: $110.69▼$119.44Volume1,155 shsAverage Volume78,226 shsMarket Capitalization$4.36 billionP/E Ratio27.83Dividend YieldN/ABeta0.82 ProfileAnalyst RatingsAdvanced ChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsSocial Media China Biologic Products Holdings, Inc. engages in the research, development, manufacture, and sale of human plasma-based biopharmaceutical products to hospitals and inoculation centers in the People's Republic of China. It offers human albumin for treating shock caused by blood loss trauma or burn; raised intracranial pressure caused by hydrocephalus or trauma; oedema or ascites caused by hepatocirrhosis and nephropathy; and neonatal hyperbilirubinemia, as well as for the prevention and treatment of low-density-lipoproteinemia. The company also provides human immunoglobulin and IVIG for original and secondary immunoglobulin deficiency, and immunoglobulin G secondary deficiency; human hepatitis B immunoglobulin for the prevention of measles and contagious hepatitis; human rabies immunoglobulin primarily for passive immunity from bites or claws by rabies or other infected animals; and human tetanus immunoglobulin for the prevention and therapy of tetanus. In addition, it offers placenta polypeptide for the treatment of cell immunity deficiency diseases, viral infection, and leucopenia, as well as assists in postoperative healing; factor VIII for treating coagulopathies; human fibrinogen; and human prothrombin complex concentrate for treating congenital and acquired clotting factor II, VII, IX, X deficiency, as well as excessive anticoagulant, vitamin K deficiency, etc. Further, the company is developing Human fibrinogen for the treatment for lack of fibrinogen and increase human fibrinogen concentration; and artificial dura and spinal dura mater products for use in brain and spinal surgeries. The company sells its products directly, as well as through distributors. The company was formerly known as China Biologic Products, Inc. and changed its name to China Biologic Products Holdings, Inc. in July 2017. China Biologic Products Holdings, Inc. is headquartered in Beijing, the People's Republic of China.Read More Beat the Market (BTM) Rank™ 0.0 Analyst's Opinion Consensus RatingThere is not enough analysis data for China Biologic Products. Previous Next 2.2 Community Rank Outperform VotesChina Biologic Products has received 349 “outperform” votes. (Add your “outperform” vote.)Underperform VotesChina Biologic Products has received 452 “underperform” votes. (Add your “underperform” vote.)Community SentimentChina Biologic Products has received 56.43% “underperform” votes from our community.MarketBeat's community ratings are surveys of what our community members think about China Biologic Products and other stocks. Vote “Outperform” if you believe CBPO will outperform the S&P 500 over the long term. Vote “Underperform” if you believe CBPO will underperform the S&P 500 over the long term. You may vote once every thirty days. Previous Next 0.0 Dividend Strength Dividend YieldChina Biologic Products does not currently pay a dividend.Dividend GrowthChina Biologic Products does not have a long track record of dividend growth. Previous Next 0.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, China Biologic Products insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 2.73% of the stock of China Biologic Products is held by insiders.Percentage Held by InstitutionsOnly 29.13% of the stock of China Biologic Products is held by institutions. Previous Next 1.3 Earnings and Valuation Earnings GrowthEarnings for China Biologic Products are expected to grow by 7.69% in the coming year, from $4.16 to $4.48 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of China Biologic Products is 27.83, which means that it is trading at a more expensive P/E ratio than the market average P/E ratio of about 16.28.Price to Earnings Ratio vs. SectorThe P/E ratio of China Biologic Products is 27.83, which means that it is trading at a less expensive P/E ratio than the Medical sector average P/E ratio of about 28.92.Price to Book Value per Share RatioChina Biologic Products has a P/B Ratio of 2.45. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities. Previous Next Analyst Opinion: 0.0Community Rank: 2.2Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 1.3 5 -4 -3 -2 -1 -Overall Beat the Market Rank™0.69 out of 5 stars Industry, Sector and Symbol Stock Exchange NASDAQ Industry Biological products, except diagnostic Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:CBPO Previous Symbol CUSIPN/A CIK1369868 Webwww.chinabiologic.com Phone86-10-6598-3111Debt Debt-to-Equity RatioN/A Current Ratio10.51 Quick Ratio8.86Price-To-Earnings Trailing P/E Ratio27.83 Forward P/E Ratio26.61 P/E GrowthN/A Sales & Book Value Annual Sales$503.70 million Price / Sales8.65 Cash Flow$4.97 per share Price / Cash Flow22.25 Book Value$45.09 per share Price / Book2.45Profitability EPS (Most Recent Fiscal Year)$4.28 Net Income$138.81 million Net Margins28.80% Return on Equity10.01% Return on Assets9.16%Miscellaneous Employees2,269 Outstanding Shares39,360,000Market Cap$4.36 billion Next Earnings Date8/3/2020 (Estimated) OptionableOptionable NASDAQ:CBPO Rates by TradingView Receive CBPO News and Ratings via Email Sign-up to receive the latest news and ratings for CBPO and its competitors with MarketBeat's FREE daily newsletter. China Biologic Products (NASDAQ:CBPO) Frequently Asked Questions How has China Biologic Products' stock been impacted by COVID-19 (Coronavirus)? China Biologic Products' stock was trading at $115.86 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization (WHO). Since then, CBPO shares have decreased by 4.5% and is now trading at $110.69. View which stocks have been most impacted by Coronavirus. When is China Biologic Products' next earnings date? China Biologic Products is scheduled to release its next quarterly earnings announcement on Monday, August 3rd 2020. View our earnings forecast for China Biologic Products. How were China Biologic Products' earnings last quarter? China Biologic Products Holdings Inc (NASDAQ:CBPO) posted its quarterly earnings data on Wednesday, May, 20th. The biopharmaceutical company reported $1.56 earnings per share for the quarter, topping the Zacks' consensus estimate of $1.38 by $0.18. The biopharmaceutical company earned $162.59 million during the quarter. China Biologic Products had a net margin of 28.80% and a return on equity of 10.01%. During the same period in the prior year, the business posted $1.11 EPS. View China Biologic Products' earnings history. Has China Biologic Products been receiving favorable news coverage? Media coverage about CBPO stock has been trending somewhat negative recently, InfoTrie Sentiment Analysis reports. The research firm rates the sentiment of press coverage by analyzing more than six thousand news and blog sources. The firm ranks coverage of publicly-traded companies on a scale of -5 to 5, with scores nearest to five being the most favorable. China Biologic Products earned a media sentiment score of -1.9 on InfoTrie's scale. They also gave media headlines about the biopharmaceutical company a news buzz of 8.0 out of 10, meaning that recent press coverage is very likely to have an effect on the stock's share price in the near future. View the latest news aboutChina Biologic Products. Who are some of China Biologic Products' key competitors? Some companies that are related to China Biologic Products include NOVOZYMES A/S/S (NVZMY), BioNTech (BNTX), Neurocrine Biosciences (NBIX), BIO-TECHNE (TECH), Qiagen (QGEN), argenx (ARGX), Repligen (RGEN), Allogene Therapeutics (ALLO), Acceleron Pharma (XLRN), Adaptive Biotechnologies (ADPT), Spark Therapeutics (ONCE), Iovance Biotherapeutics (IOVA), Crispr Therapeutics (CRSP), Ablynx (ABLYF) and bluebird bio (BLUE). View all competitors. What other stocks do shareholders of China Biologic Products own? Based on aggregate information from My MarketBeat watchlists, some companies that other China Biologic Products investors own include Lexicon Pharmaceuticals (LXRX), NVIDIA (NVDA), Gilead Sciences (GILD), Alibaba Group (BABA), Sarepta Therapeutics (SRPT), AbbVie (ABBV), Advanced Micro Devices (AMD), Amgen (AMGN), Biogen (BIIB) and Micron Technology (MU). Who are China Biologic Products' key executives? China Biologic Products' management team includes the following people: Mr. Ming Yang, Chief Financial Officer (Age 47)Mr. Ming Yin, Sr. VP (Age 41)Ms. Zhijing Liu, Corp. VP (Age 65)Mr. Gang Yang, Corp. VP & GM of Guizhou Taibang (Age 54)Dr. Bing Li Ph.D., CEO & Director (Age 51) What is China Biologic Products' stock symbol? China Biologic Products trades on the NASDAQ under the ticker symbol "CBPO." Who are China Biologic Products' major shareholders? China Biologic Products' stock is owned by many different retail and institutional investors. Top institutional investors include Maso Capital Partners Ltd (2.36%), York Capital Management Global Advisors LLC (2.16%), BlackRock Inc. (0.98%), Pentwater Capital Management LP (0.41%), BFAM Partners Cayman Ltd (0.32%) and Nikko Asset Management Americas Inc. (0.29%). View institutional ownership trends for China Biologic Products. Which major investors are selling China Biologic Products stock? CBPO stock was sold by a variety of institutional investors in the last quarter, including York Capital Management Global Advisors LLC, Nikko Asset Management Americas Inc., Nikko Asset Management Americas Inc., Parametric Portfolio Associates LLC, Voloridge Investment Management LLC, UBS Group AG, Invesco Ltd., and State Street Corp. View insider buying and selling activity for China Biologic Products. Which major investors are buying China Biologic Products stock? CBPO stock was acquired by a variety of institutional investors in the last quarter, including Maso Capital Partners Ltd, BFAM Partners Cayman Ltd, Pentwater Capital Management LP, Myriad Asset Management Ltd., Deutsche Bank AG, Aigen Investment Management LP, Pictet Asset Management Ltd., and JPMorgan Chase & Co.. View insider buying and selling activity for China Biologic Products. How do I buy shares of China Biologic Products? Shares of CBPO can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. What is China Biologic Products' stock price today? One share of CBPO stock can currently be purchased for approximately $110.69. How big of a company is China Biologic Products? China Biologic Products has a market capitalization of $4.36 billion and generates $503.70 million in revenue each year. The biopharmaceutical company earns $138.81 million in net income (profit) each year or $4.28 on an earnings per share basis. China Biologic Products employs 2,269 workers across the globe. What is China Biologic Products' official website? The official website for China Biologic Products is www.chinabiologic.com. How can I contact China Biologic Products? China Biologic Products' mailing address is 18TH FL JIALONG INTERNATIONALBUILDING 19 CHAOYANG PARK ROAD CHAOYANG DISTRICT, BEIJING F4, 100125. The biopharmaceutical company can be reached via phone at 86-10-6598-3111 or via email at [email protected] This page was last updated on 6/4/2020 by MarketBeat.com Staff
